Daily Market Reports | 10:00 AM
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
AEL (2) AIM AUE BGL (2) CU6 CY5 EVN GMD HMC HRZ HUB IAG IPX (2) MEK PLS PNI PPT QBE RMD S32 STK SUN SVL TWE VEA WAF WDS WIA
CU6 CLARITY PHARMACEUTICALS LIMITED
Medical Equipment & Devices - Overnight Price: $1.90
Canaccord Genuity rates ((CU6)) as Buy (1) -
Canaccord Genuity lowered the target price on Clarity Pharmaceuticals after the company announced it will close SAR-BBN for prostrate cancer and Sartate for neuroblastoma trials, as it prioritises other assets.
The broker notes the first commercial-scale agreement has been signed with Nusano. The company's manufacturing is based in the US, so there's no tariff impact.
The broker's current share valuation incorporates two programs -- SAR-bisPSMA for prostate cancer diagnosis and therapy, and Sartate for neuroendocrine tumour diagnosis.
Buy. Target price $6.74.
This report was published on April 17, 2025.
Target price is $6.74 Current Price is $1.90 Difference: $4.84
If CU6 meets the Canaccord Genuity target it will return approximately 255% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 15.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 12.10.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 23.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 8.19.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
HMC HMC CAPITAL LIMITED
Wealth Management & Investments - Overnight Price: $4.57
Jarden rates ((HMC)) as Overweight (2) -
Jarden has lowered the profile for AUM growth for HMC Capital, noting the outlook for earnings and valuation depends on the ability to raise unlisted capital.
The base case scenario assumes $8bn of total acquisitions from 1H25-1H28, which resulted in the underlying FFO/share forecast declining -5.4% in FY25 and -23.7% in FY26.
The broker also highlighted the bull and base case scenarios where acquisitions rise by $18.75bn and $5.5bn during this period, and FFO/share forecast comes in at 33.1c and 18.3c in FY26, respectively, vs the base case of 25.3c.
Overweight. Target cut to $6.85 from $8.65.
This report was published on April 14, 2025.
Target price is $6.85 Current Price is $4.57 Difference: $2.28
If HMC meets the Jarden target it will return approximately 50% (excluding dividends, fees and charges).
Current consensus price target is $8.47, suggesting upside of 92.9%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 12.00 cents and EPS of 27.40 cents.
At the last closing share price the estimated dividend yield is 2.63%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.68.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 50.8, implying annual growth of 169.1%.
Current consensus DPS estimate is 12.0, implying a prospective dividend yield of 2.7%.
Current consensus EPS estimate suggests the PER is 8.6.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 12.00 cents and EPS of 25.30 cents.
At the last closing share price the estimated dividend yield is 2.63%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 18.06.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 39.5, implying annual growth of -22.2%.
Current consensus DPS estimate is 12.2, implying a prospective dividend yield of 2.8%.
Current consensus EPS estimate suggests the PER is 11.1.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SVL SILVER MINES LIMITED
Gold & Silver - Overnight Price: $0.09
Petra Capital rates ((SVL)) as Buy (1) -
Petra Capital details Silver Mines submitted an updated development application (DA) with the NSW Department of Planning and requested the Planning Secretary determine whether or not the transmission line to power the Bowdens Project will form part of a single proposed development.
The broker highlights the outcome of the determination will allow the company to progress with the re-determination of the DA for the Bowdens Project.
Buy rating retained. Target price 17c.
This report was published on April 17, 2025.
Target price is $0.17 Current Price is $0.09 Difference: $0.076
If SVL meets the Petra Capital target it will return approximately 81% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY25:
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 0.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 15.67.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.27.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE
If you already had your free trial, why not join as a paying subscriber? CLICK HERE